The CD4/CD8 ratio has been associated with the risk of AIDS and non-AIDS events. We describe trends in immunological parameters in people who underwent a switch to monotherapy or dual therapy, compared to a control group remaining on triple antiretroviral therapy (ART).
Mussini, C., Lorenzini, P., Cozzi-Lepri, A., Marchetti, G., Rusconi, S., Gori, A., et al. (2018). Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study. BMC MEDICINE, 16(1), 79 [10.1186/s12916-018-1046-2].
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study
Ceccherini Silberstein F.;Andreoni M.;
2018-01-01
Abstract
The CD4/CD8 ratio has been associated with the risk of AIDS and non-AIDS events. We describe trends in immunological parameters in people who underwent a switch to monotherapy or dual therapy, compared to a control group remaining on triple antiretroviral therapy (ART).File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
2018_Switching to dualmonotherapy determines ai incresw in CD8 in HIV infected_BMC Medicines.pdf
accesso aperto
Licenza:
Creative commons
Dimensione
486.15 kB
Formato
Adobe PDF
|
486.15 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.